II. 4 The gut microbiome and dysbiosis

You get to know the invisible ecosystem living in your bowel: what the microbiome is, why diversity matters, and what dysbiosis means – the loss of balance that is the real breeding ground for the return of C. difficile.

What is the microbiome?

In your bowel you are not alone: several trillion bacteria, fungi and other tiny living beings live there in a continuously working, coordinated community. This living community is collectively called the microbiome^[G] – and the entirety of the bacteria living in it is called the microbiota^[G]. Though invisible, this community is one of our most important "organs": it carries out numerous tasks that our own body is not capable of on its own.

These beneficial inhabitants, for example, help digest the fibres that your body could not break down on its own, and meanwhile they produce valuable substances that nourish the bowel wall. They train your immune system to recognise what is friend and what is foe. And – as you saw in the previous chapters – they occupy the space and the nutrients from pathogens, maintaining the protective colonisation resistance^[G].

The secret of how it works is diversity. A healthy gut microbiome contains several hundred to a thousand different bacterial species, each carrying out a different task. This richness is what makes the community stable and resistant: if there are many kinds of inhabitants, the system can balance out smaller disturbances. The poorer and more one-sided the flora, the more fragile it is.

When the balance is upset: dysbiosis

Dysbiosis^[G] means the state in which this delicate balance is upset: diversity decreases, some of the beneficial inhabitants disappear, and ground is gained by those that under normal conditions would stay in the background. The flourishing, diverse city becomes poor, deserted streets, where there is no longer anything to protect order.

From the point of view of C. difficile infection, dysbiosis is the key concept. As the guiding idea of the book also states: C. difficile is not a simple infection but the consequence of dysbiosis. When the flora thins out – most often because of antibiotics – C. difficile can multiply precisely in this emptied-out space. And as long as the dysbiosis persists, the infection can return again and again, however much we fight it with repeated antibiotic courses.

This is why durable recovery cannot be achieved purely by overcoming the pathogen – the dysbiosis itself must be reversed. There are two ways to restore the diverse flora: on the one hand, to replace the missing beneficial community directly (this is what DiffBiome FMT^[G] does, which the next chapter is about), and on the other, to create the conditions under which this community can flourish – many kinds of fibre-rich food, good sleep, less stress. The coming weeks of the programme build up exactly this in you.

Diversity as a goal

One of the recurring messages of the programme is diversity. It is not just about "eating healthily" – but about consuming as many kinds of plant sources as possible: people who eat more than 30 different plants a week have a more diverse gut flora than those who eat fewer than 10 (McDonald D 2018 [083]) – because fibres of different structure do not feed the same bacteria (Chung 2016 [117]; Deehan 2020 [118]). A one-sided diet fattens up a few inhabitants while starving many; a varied diet containing many plants nourishes the whole community, and with it strengthens diversity, that is, protection.

Right now, during the course, this is not yet your main task – your bowel is still healing, and the gentle, easily digestible diet is what is appropriate. But it is worth being aware of the goal already: over the coming weeks, gradually, with small daily steps, we build up the varied diet and lifestyle that keep your flora diverse and resistant over the long term.

🍽️ Eating during these days

During these three days you get to know what the microbiome and dysbiosis are – and that for durable recovery the diverse flora must be rebuilt. Eating still follows the gentle line for now: plenty of fluids, easily digestible but not one-sided foods, with soluble fibre. On days 13 and 14, pair every meal with something gentle and plant-based, and pay attention to the flora's "environment" too – enough sleep, less stress – because these help engraftment just as much as food does.

From day 15 a new stage begins: from this day on, the Plant Calendar recommends one specific plant source for each day, along the gentle, firming line. The plant of day 15 is the green banana, which is rich in resistant starch: this type of starch "resists" digestion in the small intestine, reaches the large intestine intact, and there nourishes the good bacteria while supporting a firmer stool. A ripe but still slightly firm banana is a perfect start at this point – and from here on, a new gentle source will come for each day.

Why does this matter?

If you understand that the real basis for the return of C. difficile is dysbiosis – the thinning-out and loss of balance of the flora – then you also understand why rebuilding a diverse flora is the durable solution. DiffBiome replaces the missing community, while you, with your lifestyle over the coming weeks, create the environment in which this community can flourish.

References

[003] Reed AD, Theriot CM. Contribution of Inhibitory Metabolites and Competition for Nutrients to Colonization Resistance against Clostridioides difficile by Commensal Clostridium**. Microorganisms. 2021. Link

This review examines how commensal *Clostridium* species mediate colonization resistance against C. difficile. Commensal *Clostridia* modify primary bile acids into secondary bile acids that suppress C. difficile spore germination and vegetative outgrowth. They additionally produce antimicrobial peptides and short-chain fatty acids that directly inhibit C. difficile and compete for limiting nutrients such as proline, important for C. difficile growth via Stickland fermentation. Loss of commensal *Clostridia* after broad-spectrum antibiotics is a key mechanistic step toward CDI susceptibility. The authors conclude from this that new therapies against CDI are urgently needed; the clinical validation of defined *Clostridium* consortia comes not from this review but from the VE303 phase 2 trial [56].

[036] Chassaing B, Koren O, Goodrich JK, Poole AC, Srinivasan S, Ley RE, Gewirtz AT. Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome. Nature. 2015. Link

Landmark Nature paper showing that two ubiquitous dietary emulsifiers – carboxymethylcellulose (CMC, E466) and polysorbate-80 (P80, E433) – induced low-grade intestinal inflammation even at relatively low concentrations, altered microbiota composition, and produced obesity/metabolic syndrome in wild-type mice. The authors themselves note that the extent of human emulsifier consumption is not tracked, but that, given how widespread emulsifiers are in food production, actual human exposure may exceed the 1.0 percent level used in the experiment. In mice predisposed to colitis, the same compounds triggered overt colonic inflammation. The authors propose emulsifier exposure as a contributor to the post-1950 rise in IBD and metabolic disease. A corrigendum has been issued for the paper (Corrigendum: *Nature* 2016;536(7615):238). This is the central evidence cited in Section 8.3 of this Guide regarding industrial food production as a chronic input into dysbiosis.

[037] Chassaing B, Van de Wiele T, De Bodt J, Marzorati M, Gewirtz AT. Dietary emulsifiers directly alter human microbiota composition and gene expression ex vivo potentiating intestinal inflammation. Gut. 2017. Link

Follow-up to Chassaing 2015 extending the findings from mice to a human-microbiota model (the M-SHIME ex vivo system). Both emulsifiers increased the pro-inflammatory potential of the microbiota, demonstrably so through elevated flagellin levels; the composition of the community, however, was altered only by P80, while the effect of CMC operated through microbiota gene expression. The rise in lipopolysaccharide levels occurred only with P80, and at higher doses. When a suspension of the emulsifier-treated microbiota was administered to immunodeficient (RAG−/−) mice, serum IL-6 levels rose significantly. The work confirms that the murine findings translate to human gut ecology and reinforces the argument that dietary reform is a clinical, not an aesthetic, component of the maintenance phase.

[044] Wang S, Xiang L, Li F, Deng W, Lv P, Chen Y. Butyrate Protects against Clostridium. difficile Infection by Regulating Bile Acid Metabolism. Microbiol Spectr. 2023. Link

Mechanistic CDI study showing that butyrate, a short-chain fatty acid produced by commensal Firmicutes, exerts a protective effect against CDI through multiple synergistic pathways: enhanced gut barrier integrity, anti-inflammatory action, and modulation of bile acid metabolism via bile salt hydrolase regulation and FXR activation. CDI patients have markedly reduced fecal butyrate compared to controls. The findings establish a metabolic mechanism by which a healthy, diverse microbiota resists CDI colonisation – and by which a dysbiotic microbiota becomes permissive. This underpins the SCFA-related reasoning in Section 2.2 about depleted SCFA synthesis in chronic dysbiosis.

[048] Weingarden A, González A, Vázquez-Baeza Y, Weiss S, Humphry G, Berg-Lyons D, Knights D, Unno T, Bobr A, Kang J, Khoruts A, Knight R, Sadowsky MJ. Dynamic changes in short- and long-term bacterial composition following fecal microbiota transplantation for recurrent Clostridium. difficile infection. Microbiome. 2015. Link

Longitudinal microbiome characterisation following FMT in four patients with recurrent CDI, sampling daily for 28 days and weekly to 84 days post-treatment, over a total of 151 days. The recipient microbiota rapidly normalised from a markedly dysbiotic state to a healthy-range composition within days. Composition continued to change thereafter, diverging from the original donor implant material and fluctuating dynamically over both the short and the long term – while remaining throughout within the cloud of healthy microbiota. The paper supports the framing in this Guide that successful MTT produces a self-sustaining recipient ecology, not a permanent donor-tracked imprint.

[067] Suez J, Korem T, Zeevi D et al. Artificial sweeteners induce glucose intolerance by altering the gut microbiota. Nature. 2014. Link

Non-caloric artificial sweeteners (NAS) induced glucose intolerance in mice and humans via compositional and functional changes in the gut microbiota. Antibiotic treatment abrogated the deleterious metabolic effects, and germ-free mice receiving faecal transplants from NAS-consuming mice (or NAS-incubated microbiota) developed glucose intolerance. NAS-altered microbial metabolic pathways were linked to metabolic disease susceptibility, with similar dysbiosis and glucose intolerance demonstrated in healthy human subjects. The findings call for reassessment of widespread NAS use.

[069] Suez J, Cohen Y, Valdés-Mas R et al. Personalized microbiome-driven effects of non-nutritive sweeteners on human glucose tolerance. Cell. 2022. Link

Randomised controlled trial in 120 healthy adults receiving saccharin, sucralose, aspartame or stevia (in doses below acceptable daily intake) versus glucose-vehicle or no supplement for 2 weeks. All four non-nutritive sweeteners distinctly altered the stool/oral microbiome and plasma metabolome; saccharin and sucralose significantly impaired glycaemic responses. Gnotobiotic mice colonised with microbiomes from top and bottom human responders reproduced donor-specific glycaemic responses, demonstrating that non-nutritive sweeteners can induce person-specific, microbiome-dependent glycaemic alterations.

[083] McDonald D, Hyde E, Debelius JW et al. American Gut: an Open Platform for Citizen Science Microbiome Research. mSystems. 2018. Link

The American Gut Project compared >10 000 citizen-scientist stool samples from the US, UK and Australia with environmental samples using Earth Microbiome Project standardized protocols. Human stool microbiomes showed unexpectedly wide beta-diversity compared with environmental samples. Open data integration enabled discovery of new molecules and untargeted-metabolomic associations with diverse plant intake (a stronger predictor than reductive categorical variables like veganism). The work demonstrates feasibility of mail-shipped, self-collected microbiome samples for reproducing known and revealing new associations, including psychiatric illness links and individual perturbations such as surgery.

[117] Chung WSF, Walker AW, Louis P, Parkhill J, Vermeiren J, Bosscher D, Duncan SH, Flint HJ. Modulation of the human gut microbiota by dietary fibres occurs at the species level. BMC Biol. 2016. Link

Two structurally distinct non-digestible polysaccharides — **inulin and pectin** — were supplied as energy sources in a controlled fermentation system seeded with human faecal microbiota. The two fibres favoured **different bacterial species**: pectin strongly promoted *Eubacterium eligens*, inulin other groups. The authors conclude that the effect of non-digestible carbohydrates operates at the **species level**, not merely at higher taxonomic ranks. This entry is the source for the III.3 claim that fibre sources of differing carbohydrate structure select different bacterial populations. Important: a controlled fermentation system with human microbiota, not a dietary intervention trial in patients.

[118] Deehan EC, Yang C, Perez-Muñoz ME, Nguyen NK, Cheng CC, Triador L, Zhang Z, Bakal JA, Walter J. Precision Microbiome Modulation with Discrete Dietary Fiber Structures Directs Short-Chain Fatty Acid Production. Cell Host Microbe. 2020. Link

Randomised controlled human trial supplying structurally **distinct corn-starch-based fibres**. The different fibre structures shaped microbiota composition and the resulting **short-chain fatty acid profile differently** — notably the amount of butyrate. The magnitude of response also depended on baseline microbiota composition (individualised response). The authors frame this as *precision microbiome modulation*: choosing the fibre structure can direct the fermentation output. This entry is the source for the III.3 claim that variety supports a broader functional repertoire. Important: healthy adults, not an FMT or CDI population.